<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940805-2-00140</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The Informed Consent document should indicate any possible adverse medical  <!-- PJG 0012 frnewline --> consequences that may occur if the subjects withdraw from the study once the  <!-- PJG 0012 frnewline --> study has started.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;a&hyph;(6). Costs.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``The subjects should be provided with specific information about any financial  <!-- PJG 0012 frnewline --> costs associated with their participation in the protocol and in the long-term  <!-- PJG 0012 frnewline --> follow-up to the protocol that are not covered by the investigators or the  <!-- PJG 0012 frnewline --> institution involved.  <!-- PJG 0012 frnewline --> ``Subjects should be provided an explanation about the extent to which they will  <!-- PJG 0012 frnewline --> be responsible for any costs for medical treatment required as a result of  <!-- PJG 0012 frnewline --> research-related injury.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=71 g=1 f=1 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b. Specific Requirements of Gene Transfer Research  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(1). Reproductive considerations.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``To avoid the possibility that any of the reagents employed in the gene transfer  <!-- PJG 0012 frnewline --> research could cause harm to a fetus/child, subjects should be given information  <!-- PJG 0012 frnewline --> concerning possible risks and the need for contraception by males and females  <!-- PJG 0012 frnewline --> during the active phase of the study. The period of time for the use of  <!-- PJG 0012 frnewline --> contraception should be specified.  <!-- PJG 0012 frnewline --> ``The inclusion of pregnant or lactating women should be addressed.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(2). Long-term follow-up.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``To permit evaluation of long-term safety and efficacy of gene transfer, the  <!-- PJG 0012 frnewline --> prospective subjects should be informed that they are expected to cooperate in  <!-- PJG 0012 frnewline --> long-term follow-up that extends beyond the active phase of the study. The  <!-- PJG 0012 frnewline --> Informed Consent document should include a list of persons who can be  <!-- PJG 0012 frnewline --> contacted in the event that questions arise during the follow-up period. The  <!-- PJG 0012 frnewline --> principal investigator should request that subjects continue to provide a current  <!-- PJG 0012 frnewline --> address and telephone number.  <!-- PJG 0012 frnewline --> ``The subjects should be informed that any significant findings resulting from the  <!-- PJG 0012 frnewline --> study will be made known in a timely manner to them and/or their parent or  <!-- PJG 0012 frnewline --> guardian including new information about the experimental procedure, the  <!-- PJG 0012 frnewline --> harms and benefits experienced by other individuals involved in the study, and  <!-- PJG 0012 frnewline --> any long-term effects that have been observed. <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(3). Request for autopsy. <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  ``To obtain vital information about the safety and efficacy of gene transfer,  <!-- PJG 0012 frnewline --> autopsies are to be performed, if feasible. Subjects should be informed that at  <!-- PJG 0012 frnewline --> the time of death, no matter what the cause, permission for any autopsy will be  <!-- PJG 0012 frnewline --> requested of their families. Subjects should be asked to advise their families of  <!-- PJG 0012 frnewline --> the request and of its scientific and medical importance.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=3 --> Appendix M&hyph;I&hyph;D&hyph;2&hyph;b&hyph;(4). Interest of the  <!-- PJG 0012 frnewline --> media and others in the research.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> ``To alert subjects that others may have an interest in the innovative character of  <!-- PJG 0012 frnewline --> the protocol and in the status of the treated subjects, the subjects should be  <!-- PJG 0012 frnewline --> informed of the following: (i) that the institution and investigators will make  <!-- PJG 0012 frnewline --> efforts to provide protection from the media in an effort to protect the  <!-- PJG 0012 frnewline --> participants' privacy, and (ii) that representatives of applicable Federal agencies  <!-- PJG 0012 frnewline --> (e.g., the National Institutes of Health and the Food and Drug Administration),  <!-- PJG 0012 frnewline --> representatives of collaborating institutions, vector suppliers, etc., will have  <!-- PJG 0012 frnewline --> access to the subjects' medical records.''  <!-- PJG 0012 frnewline --> I accept this recommendation, and Appendix M&hyph;I&hyph;D, Informed Consent, of the  <!-- PJG 0012 frnewline --> NIH Guidelines will be added accordingly.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> B. Amendment to Appendix M&hyph;VI of the NIH Guidelines Regarding Procedures  <!-- PJG 0012 frnewline --> to be Followed for Expedited Review of Single Patient Human Gene Transfer Experiments  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            